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Abstract
Background: Obesity is a significant public health problem and innovative treatments are needed. The purpose of
this pilot study was to assess the preliminary efficacy and safety of a combined treatment of low-level laser therapy
(LLLT) and lorcaserin on weight loss, health quality of life (QOL) measures, and cardiovascular risk factors.
Methods: Forty-five overweight and obese adult participants with a body mass index (BMI) >26.9 and <40 were
randomized to receive LLLT, lorcaserin, or a combination of the two therapies. All study participants received
treatment for 3 months and were followed for 3 months post-treatment. Participants were recruited from June
2014 through September 2014.
Results: The majority of the 44 participants accrued to this study were female (84 %) with an average age of 43.
9 years (range 22 to 64 years). Most participants (93 % LLLT alone, 87 % LLLT + lorcaserin) completed at least 80 %
of the LLLT treatments. From baseline to end of treatment, significant reductions in waist circumference were noted for
each treatment group (-2.3 ± 4.1 cm, -6.0 ± 7.3 cm, and -4.0 ± 5.5 cm for LLLT, lorcaserin and combination respectively);
however, the reduction in body weight was only significant in those receiving lorcaserin and combination treatment
(-0.4 ± 1.5 kg, -1.3 ± 1.2 kg and -1.3 ± 1.3 kg). No significant differences were noted between the groups. Self-reported
satisfaction was higher in the lorcaserin versus the LLLT group.
Conclusion: This small pilot demonstrates that when combined with behavioral intervention, Lorcaserin and LLLT may
be effective components of a comprehensive approach to the treatment of overweight and obesity in the clinical
setting. Further studies with larger sample size and longer duration of treatment and follow-up are needed to further
address efficacy.
Trial Registry Information: Trial registration: NCT02129608. Registered June 15, 2014.
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Background
In 2011–2012, approximately two-thirds of US adults
were were either obese or overweight [1, 2]. Obesity sig-
nificantly increases the risk for cardiovascular disease
and is associated with poor quality of life (QOL). Weight
reduction can modify both the risk and risk factors for
cardiovascular disease [1, 3–6]. Weight reduction
reduces blood pressure, triglycerides, and low-density
lipoprotein (LDL) cholesterol; and increases high-density
lipoprotein (HDL) cholesterol [7]. Reductions in waist
circumference (WC) reduce the inflammatory biomarker
C-reactive protein (CRP), LDL, diastolic blood pressure
and overall cardiovascular risk [8].
Recent evidence has suggested that the distribution of
adipose tissue (subcutaneous versus visceral) is more
predictive of cardiovascular risk than body mass index
(BMI) alone [9]. Central adiposity, which appears to be
the best surrogate for estimating visceral adipose tissue, can
be measured clinically as waist circumference (WC) and
waist-to-hip ratio (WHR). Two large case–control studies
have demonstrated that WC and WHR are independent
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risk factors for cardiovascular mortality [9, 10]; and measur-
ing body composition is an important component of an
effective weight loss program [11].
Unfortunately many obesity treatments are associated
with poor adherence and high recidivism. Combining
treatment modalities with different mechanisms of action
to facilitate losing weight may hold the greatest potential
for achieving meaningful weight loss, as individuals are pro-
vided with several approaches to successful weight manage-
ment. Low-level laser therapy (LLLT) is a noninvasive
body-contouring procedure designed to remove excess fat
without emitting heat, sound, or vibrations. Originally de-
signed to improve wound healing, reduce edema, and re-
lieve pain [12, 13], LLLT has been utilized as an adjunct in
Lipolysis (a process for removing fatty tissue) [12, 14–16],
and was approved by the FDA in 2010 for fat reduction
[17]. At that time the FDA identified this generic type of
device as “a device using low level laser energy for the
disruption of adipocyte cells within the fat layer for the
release of fat and lipids from these cells for non-invasive
aesthetic use.” [18]. It has also been shown to accelerate
repair, stimulate cell proliferation, and promote
vascularization in injured tissues [19]. Energy from the
lasers (1.2 to 3.6 Joules/cm2) is proposed to permeabilize
adipocyte membranes, resulting in extravasation of
intra-adipocyte lipids. Lorcaserin is a selective serotonin 2C
(5-HT2C) receptor agonist. Activation of the 5-HT2C
receptor subtype in the hypothalamus increases pro-
opiomelanocortin (POMC) production leading to weight
loss through satiety [20–22]. Lorcaserin is FDA-approved
for weight management [23] in individuals with a body
mass index (BMI) of >27 kg/m2 (overweight) when accom-
panied by a weight-related health condition such as type 2
diabetes or high blood pressure, or in people with a BMI
>30 kg/m2 (obese) [20–22].
The purpose of this study was to evaluate the safety,
feasibility, and preliminary efficacy of LLLT alone or in
combination with lorcaserin for reducing anthropo-
morphic meaures of obesity. Biomarkers and adherence
to treatment were also measured to provide guidelines
for potential future investigations.
Methods
Trial Design
This was an open-label clinical trial in which partici-
pants were randomized to one of three treatments: (1)
Lorcaserin 10 mg by mouth twice a day for 12 weeks; (2)
LLLT administered for one hour once a week for
12 weeks; or (3) combination therapy with lorcaserin
and LLLT for 12 weeks.
Setting
A total of 45 participants were recruited from the local
community of Rochester, MN from June 2014 through
September 2014. Of these 45 individuals, with a BMI of
27–39.9 kg/m2, who were motivated to lose weight and
enrolled in this study, 44 went on to receive study
treatment. This report is based on the 44 participants
who went on to be treated in study (Fig. 1). This
consort diagram adheres to consort guidelines on
reporting clinical trials [24].
Participants
Study recruitment was through word of mouth (73 %),
internet postings (24 %), and flyers (3 %). All interested
individuals called a central number and underwent a 10-
min phone pre-screen. If they passed the telephone pre-
screen, they were invited to attend a one-on-one consent
visit. After participants consented to be in study, they
signed a written consent form and went on to be
screened for study eligibility. If they passed the screening
procedures they were invited to participate in the study.
If they accepted the invitation, participants were ran-
domized using a computer-generated randomization
schedule. Study visits included a pre-screen phone inter-
view, a combined consent/screen visit, a baseline visit at
which the drug was dispensed and first laser treatment
delivered, and a visit every other week during the first
12 weeks of study. Participants who received LLLT re-
ported to the study office every week at approximately
the same time and same day of the week. A phone visit
was completed at week 13 (1 week after the end of treat-
ment) to assess safety and a final study visit occurred at
6 months. This study was approved by the Mayo Clinic
Institutional Review Board and written informed consent
was obtained for all study particpants.
Interventions
Low-Level Laser Treatment
The laser used in this study was an Erchonia® Zerona™
2.0 Laser. This LLLT has been approved by the Food
and Drug Administration (FDA) as a non-invasive
dermatological aesthetic treatment to reduce the circum-
ference of their hips, waist, and thighs (Section 510(k) =
K123237). Each LLLT device consists of a multiple-head
low-level diode laser with 6 independent diode laser
heads. Each diode emits 532 nm (green) laser light. In
the active LLLT [25] each diode generates a 17 milliwatt
(mW) output. In this trial, participants engaged in
weekly treatments for 12 weeks. Lasers were focused
around the stomach and abdomen for 30 min and then
aimed at the central region of their back for another
30 min. This was done once a week for 12 weeks for a
total of 12 treatments. All study participants assigned to
the laser were given instructions to wear body constrict-
ing undergarments during the 12 weeks of treatment
and to drink plenty of fluids.
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Lorcaserin
Participants were administred 10 mg orally twice daily
for 12 weeks.
Behavioral Intervention
This study was dependent on successful behavior
change, which in turn requires self-efficacy and motiv-
ation. Self-efficacy is defined as a sense of control over
one’s ability to make the change [26, 27]. In this study
we utilized a written self-help guide (My Weight Solu-
tion) to provide structure to the behavioral sessions con-
sisting of a brief 5 to10 min one-on-one behavioral
intervention at each study visit (every two weeks) based
on different sections of the manual. Using a wellness
coaching model [28], staff members personalized their
message based on the participants progress and feedback
Fig. 1 participant flow in study from first study contact to last study contact
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during the study visit, this was dependent on the partici-
pants confidence and motivational level. When confi-
dence was low, participants were encouraged to problem
solve, use goal setting skills, seek social support, and
think about their pass successes. When motivation was
low, personal reasons for seeking to lose weight were
reviewed to enhance motivation. Study staff received
training and supervision from a weight management
behavioral expert (MMC).
Outcomes
Subjects’ motivation to reduce weight, follow a healthy
diet, and maintain a physically active lifestyle were
assessed at baseline prior to study interventions. Other
assessments collected at baseline, end-of-treatment, and
end-of-study included the following: (1) the Impact of
Weight on Quality of Life-Lite (IWQOL-Lite) assess-
ment, to assess self-perception on how weight affects
daily physical health and emotional well-being [29, 30];
(2) the Linear Analogue Self-Assessment (LASA) to
assesses QOL [31–33]; (3) the Body Areas Satisfaction
Scale (BASS), a scale that is actually a sub-scale from the
Multidimensional Body-Self Relations Questionnaire
(MBSRQ) and used to assess patients’ self-perceived
body image and satisfaction of 8 specific body areas
[34–36]; and 4) the Body Appreciation Scale (BAS),
assessment of positive body image [37]. Safety measures in-
cluded adverse events information, concomitant medication
information, and self report for despressive symptoms-
reported depression using the Center for Epidemiologic
Studies Depression Scale Revised (CESD-R). Biomarkers
included blood leukocyte count, CRP, adipokines (leptin,
adiponectin), cholesterol profile, HgbAlc and blood glucose.
Anthropomorphic measures of weight, WC and hip
circumference (HC) were collected. WHR were derived
from the participants’ WC and HC. BMI and WHR were
derived from measurement of weight, height, and waist and
hip circumference. The measurements were as follows:
Height of the subject in stocking feet were measured to the
nearest 0.5 cm using a wall-mounted vertical stadiometer;
Weight was measured wearing undergarments and no
shoes to the nearest 0.1 kg by using a balance-beam scale
calibrated weekly with certified weights. BMI was calculated
using the standard formula of kg/m2; WC was measured by
using a soft measuring tape placed in a horizontal plane
around the abdomen midway between the lowest rib and
the superior border of the iliac crest (the tape was snug but
not compressing the skin and parallel to the floor with the
measurement being made at the end of a normal expir-
ation with the subject in an upright position); HC was
measured at the maximal protrusion of the buttocks.
Circumference was given as the mean of two measure-
ments to the nearest 0.1 cm; WHR was calculated from
the waist and hip measurements; Adherence to the study
interventions was recorded as either attendance to the
laser treatements and/or self report of pills taken per day
on the subjects daily diaries, in addition to counting of
pills dispensed and returned.
Study Schedule
All subjects completed in person study visits every other
week during the 12 weeks of treatment. This was
followed by a safety phone call contact 1 week after the
final treatment study visit and one final study visit at
week 24. Vital signs and anthropomorphic measure-
ments were collected at every study visits prior to any
intervention, including behavioral intervention, adverse
events, and concomitant medications. Study outcome as-
sessments (IWQOL-Lite, LASA, BASS, BAS and CESD)
and fasting biomarkers were collected at weeks 0 (base-
line), 6, 12, and 24. During the final visit, satisfaction
was measured via an end-of-study self-assessment survey.
The 12 questions included “On a scale of 1 to 4, where “0”
is not satisfied at all and “4” is extremely satisfied, how sat-
isfied were you with your treatment assignment?”; other
questions focused on the subjects’ perception of “effective-
ness,” “usefulness,” and “difficulty.”
Statistical Analysis
The primary endpoint was change in WC, per measure-
ments taken at baseline and week 12. Based on prelimin-
ary data, the standard deviation for this endpoint was
estimated to be 6.4 cm [38]. Although debate exists
regarding the value of formal statistical comparisons in
phase II trials, we agree with those who propose that a
one-sided test with a false-positive (type I error) rate of
0.20 is an appropriate criterion to use to help guide the
decision making process [39]. Under the assumption
that a difference between groups of 4 cm or larger was
clinically meaningful, we determined that a sample-size
of N = 15 per group would provide statistical power
(one-tailed, alpha = 0.20) of 80 % to conclude that future
studies on combination therapy were warranted if a clin-
ically meaningful difference exists.
In all cases, data were summarized using mean ± SD
for continuous variables, and frequency percentages for
nominal variables. Treatment adherence was quantified
for each individual by calculating the percentage of treat-
ment sessions attended and the percentage of medica-
tion used. Anthropomorphic measures at 12 weeks were
compared between treatment groups using analysis of
covariance (ANCOVA) with the baseline value included
as the covariate. For these endpoints, the approach of
last-value carried forward was used to impute values for
subjects who discontinued study participation. The
comparisons of combination therapy versus LLLT and
lorcaserin monotherapies were of specific interest. For
these comparisons, the treatment effect was reported
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using a point estimate and 90 % confidence interval.
Similar analyses were performed for laboratory values
and QOL measures. In all cases, distributional as-
sumptions were assessed with transformations or non-
parametric methods used as appropriate. In all cases,
two-tailed p-values are reported. Study data were col-
lected utilizing paper source case report forms. The
data was managed using the REDCap tool hosted at
Mayo Clinic. Data analyses were conducted using SAS
statistical software (version 9.3, SAS Institute, Inc.,
Cary, NC).
Results
A total of 122 individuals called with interest in this
study,45 individuals were enrolled and randomized to
study groups (15 LLLT, 15 lorcaserin, 15 combination
therapy) and 44 went on to be treated according to their
randomized assignment (15 LLLT, 14 lorcaserin, 15
combination therapy). This report is based on the 44
who went on to be treated in study (Fig. 1).
Baseline participant characteristics are presented in
Table 1. The majority of participants were females
(84 %), married or living as married (64 %), with at least
some college education (95 %); their average age was
43.9 years (range 22 to 64 years). No significant differ-
ences were detected between the groups at baseline.
Anthromporhic Measurements
At week 12, a significant decrease in WC from baseline to
end-of-treatment (week 12) was observed for all treatment
groups (-2.3 ± 4.1 cm, -6.0 ± 7.3 cm, and -4.0 ± 5.5 cm for
the LLLT, lorcaserin, and combination groups, respect-
ively; P < .05), as seen in Table 2. Significant reductions
from baseline to week 12 were also observed for weight,
BMI, and HC in the lorcaserin and combination groups.
No significant differences were observed between treat-
ment groups for any of the body measures assessed. At
6 months, the mean change in weight from baseline was
negative for all treatment groups, and significantly
different from baseline for the combination group (-1.4 ±
3.6 kg, P = .154; -2.4 ± 5.1 kg, P = .097; and -2.0 ±
3.5 kg, P = .045 for LLLT, lorcaserin, and combination
groups, respectively). The change in weight from
baseline to 6 months for the combination group was
not significantly different from LLLT (P = .773) or lorca-
serin (P = .775). The mean change in WC from baseline to
6 months was also negative for all treatment groups (-2.8 ±
4.3 cm, P = .023; -5.1 ± 8.8 cm, P = .051; and -2.8 ± 5.2 cm,
P = .059 for LLLT, lorcaserin, and combination groups,
respectively). The change in WC from baseline to 6 months
for the combination group was not significantly different
from LLLT (P = .942) or lorcaserin (P = .424).
Quality of Life
The QOL measures at baseline and week 12 are summa-
rized in Table 3. Overall QOL, as measured by LASA,
improved significantly in those assigned to the LLLT
group and combination therapy and the overall QOL as
measured by IWQOL improved significantly in those
assigned to combination therapy. In the lorcaserin




LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 15)
Age, years ± SD 43.9 ± 11.6 45.4 ± 9.9 40.6 ± 11.5 45.4 ± 13.3
Sex, N (%)
Male 7 (16) 2 (13) 3 (21) 2 (13)
Female 37 (84) 13 (87) 11 (79) 13 (87)
Marital Status, N (%)
Never married 5 (11) 1 (7) 1 (7) 3 (20)
Separated/divorced 9 (21) 3 (20) 2 (14) 4 (26)
Widowed 2 (4) 1 (7) 0 (0) 1 (7)
Married/living as married 28 (64) 10 (66) 11 (79) 7 (47)
Education, N (%)
≤ High school graduate 2 (4) 0 (0) 2 (14) 0 (0)
Some college 25 (57) 10 (67) 7 (50) 8 (53)
≥ 4-year college degree 17 (39) 5 (33) 5 (36) 7 (47)
Weight at baseline, kg ± SD 93.5 ± 15.0 96.0 ± 15.3 94.4 ± 16.2 90.3 ± 14.0
Waist Circumference at
baseline, cm ± SD
104.7 ± 12.6 105.3 ± 11.6 108.0 ± 15.7 100.9 ± 10.0
SD Standard Deviation
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group, self-perception of body image (BASS) and body
appreciation scale (BAS) improved between baseline and
week 12. Changes from baseline did not differ signifi-
cantly across treatment groups for any of the QOL or
body image/appreciation measures (P > .05).
Biomarkers
In the LLLT monotherapy, a significant decline between
baseline and end of treatment occured in white blood
cells and neutrophils. A significant decrease in triglycer-
ides was observed in the lorcaserin monotherapy. In the
combination therapy group, significant decreases in
neutrophils and total cholesterol were observed. No dif-
ferences were observed between groups (P > .05). Tables 4
and 5 provide the biomarker data.
Adverse Events
No serious adverse events (AEs) were observed for any
of the assigned treatment arms. Ten AEs, occurring in
the lorcaserin monotherapy and combination therapy
groups, were reported by 6 individuals as being related
to lorcaserin: dizziness (1 loracaserin, 1 combination),
nausea (1 loracaserin, 2 combination), headache (1 lora-
caserin, 2 combination), low blood pressure (1 combin-
ation), and tingling sensation (1 combination). No AEs
that “possibly,” “probably,” or “definitely” were related to
LLLT were reported.
Adherence
In the LLLT group, 93 % (14/15) attended at least 80 %
of the treatments. In the lorcaserin group, 86 % (12/14)
took at least 80 % of the dispensed doses. In the combin-
ation group, 73 % (11/15) took at least 80 % of the dis-
pensed dose and 87 % (13/15) attended at least 80 % of
the LLLT treatments. Among participants providing
information at end of treatment, 50 % (7/14) in the LLLT
group and 50 % (6/12) in the combination group reported
complying with the body constricting undergarment
Table 2 Anthropomorphic Measurements
Variable Treatment group Estimated treatment effect (90 % C.I.)a
LLLT (N = 15) ± SD Lorcaserin (N = 14) ± SD Combination
(N = 15b) ± SD
Combination vs. LLLT only Combination vs.
Lorcaserin only
Weight, kg
Baseline 96.0 ± 15.3 94.4 ± 16.2 90.3 ± 14.0
Week 12 95.0 ± 14.2 90.7 ± 17.4 86.7 ± 14.2 −2.6 (-5.0, -0.3) +0.1 (-2.3, +2.5)
Delta −1.0 ± 4.4 −3.7 ± 3.3c −3.5 ± 3.6c P = .070 P = .950
Weight loss of >5 %, n (%) 2 (13) 8 (57) 5 (33)
Body Mass Index, kg/m2
Baseline 33.5 ± 3.9 33.6 ± 5.1 33.4 ± 4.2
Week 12 33.1 ± 3.5 32.3 ± 5.7 32.1 ± 4.3 −1.0 (-1.8, -0.1) +0.0 (-0.8, +0.9)
Delta −0.4 ± 1.5 −1.3 ± 1.2c −1.3 ± 1.3c P = .063 P = .973
Waist Circumference, cm
Baseline 105.3 ± 11.6 108.0 ± 15.7 100.9 ± 10.0
Week 12 103.0 ± 11.3 102.0 ± 16.3 96.9 ± 12.4 −1.8 (-5.4, +1.7) +1.7 (-1.9, +5.4)
Delta −2.3 ± 4.1d −6.0 ± 7.3c −4.0 ± 5.5d P = .398 P = .436
Hip Circumference, cm
Baseline 119.1 ± 8.8 120.7 ± 12.1 119.0 ± 8.8
Week 12 118.1 ± 8.3 116.2 ± 12.0 116.0 ± 9.3 −2.0 (-3.6, -0.3) +1.5 (-0.2, +3.2)
Delta −1.0 ± 3.1 −4.5 ± 2.1e −3.0 ± 3.0c P = .059 P = .159
Waist-to-Hip ratio
Baseline 0.885 ± 0.086 0.892 ± 0.072 0.850 ± 0.063
Week 12 0.874 ± 0.086 0.874 ± 0.087 0.834 ± 0.068 −0.007 (-0.032, +0.018) −0.001 (-0.027, +0.025)
Delta −0.011 ± 0.035 −0.017 ± 0.053 −0.016 ± 0.032 P = .657 P = .961
CI Confidence Interval, SD Standard Deviation
aEstimated treatment effect from analysis of covariance (ANCOVA) with the baseline value of the given variable included as a covariate
bThere were 2 subjects in the combination group who discontinued prior to week 12 (one after week 2 and one after week 6). For these 2 subjects the last value
of each variable was carried forward to week 12
cp < 0.01 for paired t-test comparing week 12 versus baseline
dp < 0.05 for paired t-test comparing week 12 versus baseline
ep < 0.001 for paired t-test comparing week 12 versus baseline
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recommendation; while 50 % (7/14), 69 % (9/13), and
58 % (7/12) (LLLT, lorcaserin, and combination groups,
respectively; P = .605) indicated that they increased their
water intake.
Among the 3 treatment groups (LLLT, lorcaserin, and
combination therapy), 29 % (4/14), 54 % (7/13), and
75 % (9/12), respectively, indicated that they reduced
their caloric intake (P = .063); 64 % (9/14), 85 % (11/13),
and 92 % (11/12) indicated that they made dietary modi-
fications (P = .224); and 43 % (6/14), 54 % (7/13), and
58 % (7/12) indicated that they increased their physical
activity level (P = .784).
Satisfaction
Overall satisfaction with the program was reported as
“satisfied” or “extremely satisfied” by 29 % (4/14) in the
LLLT group, 100 % (13/13) in the lorcaserin group, and
92 % (11/12) in the combination group (P < .001).
Discussion
In this pilot project examing combined therapy for weight
management, LLLT monotherapy, lorcaserin monotherapy,
and combination therapy significantly reduced anthropo-
morphic measurements among overweight and obese
adults. These interventions were also associated with im-
provements in body satisfaction and QOL. No side effects
were reported related to LLLT and few side effects were re-
ported related to lorcaserin. Satisfaction was higher with
lorcaserin monotherapy and combination compared to
LLLT alone.
Although no significant differences were observed be-
tween groups, consistent with previous literature, all
three interventions were associated with reductions in at
least one anthroporphic measurement. In a double-
blind, placebo-controlled study (active vs. “sham” LLLT),
67 overweight patients were randomized to LLLT
(17 mW) or sham-LLLT (2.5 mW) and received 6 treat-
ments over 2 weeks. Sixty-three percent (22/35) of sub-
jects in the LLLT group participants achieved individual
success, defined as at least 3.0 in. reduction in combined
circumference measurements for waist, hip, and bilateral
thighs from baseline to after treatment phase comple-
tion, compared with 6 % (2/32) of participants in the
sham group [40]. A larger study (N = 689) from the same
investigative team indicated that the reductions in
circumference were not attributable to fluid loss or fat
relocation [41]. Retrospective studies have supported the
body measurement reductions achieved (e.g., waist, hips,
thighs) with this therapy and reported concomitant
decreases in weight [42].
The treatment and efficacy of lorcaserin for weight
loss has been evaluated in three large phase III clinical
trials, with over 8,000 overweight and obese subjects, in
which a weight loss of 3 % to almost 4 % was found at
1 year. The Behavioral Modification and Lorcaserin for
Overweight and Obesity Management (BLOOM) trial
enrolled 3,182 subjects and observed an average weight
loss of 5.8 ± 0.2 kg with lorcaserin and 2.2 ± 0.1 kg with
placebo during year 1 (P < .001) [20]. The Behavioral
Modification and Lorcaserin Second Study of Obesity
Management (BLOSSOM) trial enrolled 4,008 patients
and showed that more people lost at least 5 % of their
body weight at one year compared to placebo (47 %,
40 %, vs. 25 %; P < .001, lorcaserin twice daily, lorcaserin
once daily, vs. placebo, respectively) [21]. The Behavioral
Modification and Lorcaserin for Obesity and Overweight
Management in Diabetes Mellitus (BLOOM-DM) trial,
which enrolled 604 obese/overweight individuals with
diabetes observed that more patients lost ≥5 % body
weight with lorcaserin twice daily (38 %; P < .001) or lor-
caserin daily (45 %; P < .001) compared with placebo
(16 %) [22]. In our study, we observed an average weight
loss of 3.5 to 3.7 kg (combination and lorcaserin group,
Table 3 Quality of Life measures
Variable Treatment Group
LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 13a)
LASA ± SD
Baseline 8.0 ± 0.9 7.7 ± 1.8 7.4 ± 1.1
Week 12 8.6 ± 0.9 8.6 ± 0.8 8.2 ± 1.3
Delta +0.6 ± 0.9b +0.9 ± 1.9 +0.8 ± 1.2b
CES-D ± SD
Baseline 2.0 ± 3.6 4.1 ± 6.6 2.8 ± 3.3
Week 12 3.3 ± 4.4 3.7 ± 4.3 3.4 ± 2.8
Delta +1.3 ± 2.5 −0.4 ± 4.8 +0.6 ± 2.8
BAS ± SD
Baseline 3.7 ± 0.6 3.7 ± 0.5 3.7 ± 0.7
Week 12 3.6 ± 0.5 3.9 ± 0.7 3.8 ± 0.8
Delta −0.1 ± 0.6 +0.3 ± 0.4b +0.1 ± 0.7
BASS ± SD
Baseline 3.0 ± 0.4 3.0 ± 0.5 3.0 ± 0.4
Week 12 3.1 ± 0.3 3.3 ± 0.5 3.0 ± 0.8
Delta +0.1 ± 0.4 +0.3 ± 0.4b 0.0 ± 0.6
IWQOL - TOTAL ± SD
Baseline 54.1 ± 12.1 50.9 ± 15.3 62.8 ± 22.4
Week 12 47.9 ± 7.4 47.6 ± 15.6 54.9 ± 21.9
Delta −6.1 ± 10.4 −3.3 ± 8.7 −8.0 ± 7.9c
BAS Body Appreciation Scale, BASS Body Area Satisfaction Scale, CESD-R Center
for Epidemiologic Studies Depression Scale Revised, IWQOL-Lite Impact of
Weight on Quality of Life - Lite, LASA Linear Analogue Self-Assessment, SD
Standard Deviation
aOf the 15 subjects assigned to the combination group, 2 discontinued prior
to week 12 and are not included in the analysis
bP < 0.05 for paired t-test comparing week 12 versus baseline
cP < 0.01 for paired t-test comparing week 12 versus baseline
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respectively) by end of 12 weeks of treatment; whereby,
similarly to these past studies, 57 % (8/14) in the lorca-
serin group and 33 % (5/15) in the combination therapy
lost at least 5 % or more of their baseline weight by end
of treatment.
Because QOL is so important and many obese adults
report having a negative QOL [43], it is crucial to assess
the QOL of participants in weight-loss programs as it
has been reported that weight loss can improve QOL
[44]. In this study we observed that participants in the
LLLT conditions improved their QOL, which suggests
that there may be an important psychosocial dimension
of this treatment. We hypothesize that participants may
have anticipated that the LLLT would improve their
health and well-being. Given the importance of QOL to
the individual, further exploration of this QOL finding is
warranted.
Unlike the previous LLLT studies, in this study satisfac-
tion with LLLT was low; we hypothesize that this may be
related to unrealistically high expectations surrounding its
utility. Several participants expressed dissatisfaction in not
receiving LLLT and one participant went as far as refusing
to continue with the study after finding out that her ran-
domized assignment was lorcaserin monotherapy. Less
than half of the subjects assigned LLLT adhered with the
behavioral intervention instructions related to their behav-
ior changes (i.e., wearing the restrictive undergarments
during the treatment weeks and drinking plenty of water)
leading the investigators to hypothesize that, as unrealistic
as it seems, study participants assumed that the LLLT
would take care of their weight loss with little or no life-
style changes on their part.
The behavior change phenomenon of setting unrealistic
expectations and becoming disappointed when those
expectations are not met is not unusual in weight loss
programs where setting unrealistic expectations is a bar-
rier to actual weight loss [45]. For example, a study of 60
obese females (mean BMI of 36.3 kg/m2), where subjects
set a goal of 32 % reduction in body weight the average
weight loss was a little less than 17 % from their baseline
weight and the subjects deemed the program a failure
[46]. Two other studies with individuals who had a BMI of
40 kg/m2 or higher also found this same phenomenon
[47, 48]. Leading us to conclude that individuals with
higher baseline weight may have more unrealistic goals for
Table 4 Lab values
Variable LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 13a)
RBC
Baseline 4.59 ± 0.32 4.75 ± 0.43 4.80 ± 0.41
Week 12 4.61 ± 0.29 4.70 ± 0.42 4.65 ± 0.34
Delta +0.01 ± 0.20 −0.06 ± 0.17 −0.15 ± 0.26
Hemoglobin
Baseline 13.77 ± 0.92 14.34 ± 1.26 14.00 ± 1.26
Week 12 13.83 ± 0.81 14.08 ± 1.28 13.55 ± 1.15
Delta +0.07 ± 0.57 −0.26 ± 0.61 −0.45 ± 0.86
Hematocrit
Baseline 41.35 ± 2.07 42.81 ± 3.00 42.17 ± 2.82
Week 12 41.53 ± 2.13 42.03 ± 2.92 40.78 ± 2.67
Delta +0.17 ± 1.82 −0.77 ± 1.93 −1.39 ± 2.37
MCV
Baseline 90.19 ± 4.38 90.21 ± 3.18 88.09 ± 4.07
Week 12 90.29 ± 3.69 89.66 ± 3.76 87.86 ± 4.00
Delta +0.10 ± 2.05 −0.56 ± 2.08 −0.23 ± 1.86
RDW
Baseline 13.23 ± 0.74 13.11 ± 0.50 13.41 ± 0.61
Week 12 13.19 ± 0.58 12.96 ± 0.49 13.22 ± 0.69
Delta −0.04 ± 0.40 −0.14 ± 0.37 −0.19 ± 0.48
WBC
Baseline 6.83 ± 1.71 7.20 ± 1.45 6.98 ± 1.28
Week 12 5.99 ± 1.41 6.81 ± 2.11 6.32 ± 1.57
Delta −0.83 ± 1.26* −0.39 ± 1.08 −0.66 ± 1.11
Neutrophils
Baseline 4.03 ± 1.58 4.15 ± 1.12 4.29 ± 1.08
Week 12 3.30 ± 1.10 3.99 ± 1.72 3.78 ± 1.20
Delta −0.74 ± 1.17* −0.16 ± 0.99 −0.51 ± 0.77*
Lymphocytes
Baseline 2.04 ± 0.41 2.22 ± 0.55 2.00 ± 0.39
Week 12 1.93 ± 0.38 2.03 ± 0.41 1.84 ± 0.53
Delta −0.11 ± 0.25 −0.19 ± 0.43 −0.16 ± 0.39
Monocytes
Baseline 0.51 ± 0.13 0.60 ± 0.19 0.49 ± 0.13
Week 12 0.47 ± 0.13 0.58 ± 0.22 0.47 ± 0.10
Delta −0.05 ± 0.12 −0.02 ± 0.12 −0.03 ± 0.06
Eosinophils
Baseline 0.22 ± 0.12 0.18 ± 0.11 0.16 ± 0.05
Week 12 0.26 ± 0.18 0.17 ± 0.11 0.19 ± 0.15
Delta +0.04 ± 0.11 −0.01 ± 0.06 +0.03 ± 0.15
Basophils
Baseline 0.03 ± 0.02 0.04 ± 0.03 0.03 ± 0.02
Week 12 0.04 ± 0.02 0.04 ± 0.03 0.03 ± 0.01
Delta +0.01 ± 0.02 −0.00 ± 0.02 +0.00 ± 0.01
Table 4 Lab values (Continued)
Platelets
Baseline 251.4 ± 56.6 287.0 ± 69.3 292.9 ± 60.3
Week 12 253.4 ± 51.2 277.1 ± 70.9 287.4 ± 47.7
Delta +2.0 ± 20.8 −9.9 ± 27.3 −5.5 ± 26.0
*p < 0.05, for paired t-test comparing week 12 versus baseline
aOf the 15 subjects assigned to the combination group, 2 discontinued prior
to week 12 and are not included in the analysis
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weight loss and high unrealistic expectations set prior to
the program lead to poor compliance with the program
and worse outcomes [45]. This phenomenon was also
observed in our study, where subjects expected a large
weight loss while not adhering to the behavioral interven-
tions provided by study staff, indicating that in future
studies behavioral intervention should include an initial
intake discussion whereby subjects can set realistic expec-
tations with the study staff in order for the study to have
the most impact. Individuals trying to lose weight should
receive valid information at this time about the expected
outcomes of the intervention they are receiving and this,
in turn, may improve adherence with the program.
The small sample size limited the ability to detect
significant differences between groups. The open label
design limits our study due to patient selection bias [49],
participant retention bias [50], and participant perform-
ance bias [51]. In this study, participants who entered
the study had a preference for LLLT. We observed that
although they had no choice in what they were assigned,
some subjects dropped out of the study after a few treat-
ments, if it was not the treatment they wanted; while we
hypothesize that other subjects did not adhere to the
behavioral changes recommended if they received the
intervention they did not expect/prefer, we did not
track adherence to preferences and cannot confirm
this at this time.
Another potential limitation was the LLLT administra-
tion. Both in a clinical setting and in research trials,
LLLT can be provided at three different frequencies:
40 min (20 min on each side-front and back 3 times a
week (every 48 h); 60 min (30 min on each side) 2 times
a week; and 60 min (30 min on each side) once a week.
The contemporary theory postulates that the lysing of
fat cells should be continuous and the fat cells should
not be allowed to recover. When we designed the study
we sought expert opinion and it was recommended that
if we increase the duration from 20 min on each side to
30 min on each side, once a week would be adequate.
Taking into consideration the participant burden and
study attrition, we decided that this preliminary study
would focus on the last option (once per week). While
reducing the visits to once a week may have led to
improved treatment adherence, we suspect that the
treatment of the LLLT was not frequent enough to result
in clinical benefit. The study outcomes did not substan-
tiate that this was the correct decision. Another study is
currently being designed to determine the best fre-
quency, which will address the lysing of cells and the
subject burden.
In order to open recruitment to a larger number of
individuals, the BMI inclusion criteria was expanded to
include anyone with a BMI of 27–39.9, which included
those categorized as overweight (BMI 25–29.9), obese
Table 5 Lab values
Variable LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 13a)
Hgb_a1c
Baseline 5.59 ± 0.92 5.31 ± 0.51 5.36 ± 0.23
Week 12 5.71 ± 1.12 5.29 ± 0.43 5.33 ± 0.30
Delta +0.12 ± 0.29 −0.02 ± 0.14 −0.03 ± 0.13
CRP
Baseline 4.72 ± 3.22 4.71 ± 3.62 4.60 ± 2.18
Week 12 4.81 ± 2.79 4.04 ± 2.55 5.97 ± 5.69
Delta +0.09 ± 1.86 −0.68 ± 1.40 +1.37 ± 5.61
LDL
Baseline 111.3 ± 28.7 95.1 ± 19.0 117.5 ± 31.0
Week 12 115.1 ± 29.4 94.9 ± 20.8 107.0 ± 28.8
Delta +3.8 ± 22.2 −0.3 ± 17.8 −10.5 ± 22.2
Non-HDL Cholesterol
Baseline 137.5 ± 33.0 128.4 ± 27.2 141.8 ± 34.7
Week 12 139.5 ± 37.3 121.6 ± 30.7 128.7 ± 33.7
Delta +2.0 ± 24.6 −6.8 ± 18.8 −13.1 ± 24.2
HDL
Baseline 62.3 ± 14.5 53.6 ± 14.5 60.3 ± 16.7
Week 12 61.5 ± 17.5 51.3 ± 12.7 56.5 ± 15.7
Delta −0.8 ± 7.5 −2.3 ± 7.1 −3.8 ± 7.7
Triglycerides
Baseline 130.7 ± 48.7 166.1 ± 98.5 119.8 ± 51.5
Week 12 121.9 ± 62.3 134.1 ± 85.3 108.7 ± 50.1
Delta −8.9 ± 39.7 −32.1 ± 39.0** −11.2 ± 56.2
Total Cholesterol
Baseline 199.8 ± 29.0 182.0 ± 26.7 202.1 ± 27.3
Week 12 201.0 ± 35.7 172.9 ± 30.8 185.2 ± 33.0
Delta +1.2 ± 30.1 −9.1 ± 23.5 −16.8 ± 24.2*
Fasting Glucose
Baseline 89.7 ± 11.7 90.6 ± 14.6 88.6 ± 13.6
Week 12 92.5 ± 20.1 60.2 ± 17.8 87.7 ± 8.7
Delta +2.8 ± 10.9 −0.4 ± 7.0 −0.9 ± 8.1
Leptin
Baseline 38.1 ± 15.7 35.7 ± 21.2 37.2 ± 26.0
Week 12 34.0 ± 12.4 34.1 ± 23.6 30.8 ± 21.4
Delta −4.1 ± 11.6 −1.6 ± 11.3 −6.4 ± 12.1
Adiponectin
Baseline 9,719 ± 5,534 7,955 ± 3,463 12,412 ± 8,393
Week 12 8,987 ± 4,050 7,156 ± 2,231 12,254 ± 7,273
Delta −732 ± 3,970 −799 ± 2,237 −158 ± 2,787
*p < 0.05, **p < 0.01for paired t-test comparing week 12 versus baseline
aOf the 15 subjects assigned to the combination group, 2 discontinued prior
to week 12 and are not included in the analysis
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level 1 (BMI 30–34.9), and obese level II (BMI 35–39.9).
At the time that the study started, only the Zerona™ 2.0
LLLT option was available for anyone with a BMI of
≥25. After completion of the study, a second type of
LLLT was approved by the FDA. Two LLLTs are now
approved by the FDA for body sculpting: a 6-headed
green laser (K130922) for adults with a BMI of 25–
29.9 kg/m2 (NCT01702259) and a 10-headed green laser
(K142042) for patients with a BMI of 30–40 kg/m2
(NCT01821352). If indeed the 10-headed green laser
provides greater treatment effect for those individuals
with a BMI between 30–40 kg/m2, as the marketing im-
plies, then we are undertreating our patients who fall in
this range.
Another potential limitation is related to variability in
the behavioral counseling and lack of tailoring of the
behavioral intervention to LLLT. Since LLLT is a new
weight loss intervention it is not known if healthy life-
style recommendations should be tailored for LLLT, such
as more focus on strength training, use of form fitting
clothing, or nutritional guideline. In terms of the vari-
ability of the behavioral intervention, in order to accom-
modate the study participants, a large coordinating staff
was used. No study participant was guaranteed the same
staff member at all visits. While, the study staff was uni-
formly trained on the behavioral intervention approach,
the behavioral intervention had to target the subjects
personal needs and therefore varied between subjects
and staff members. As a result, the counseling approach
varied depending on the staff member. In addition, the
study staff was trained using an established protocol for
collecting body measurements. We did not perform a for-
mal study to assess variability of the measurement process.
Although variability in the measurement process contrib-
utes to the variability seen in body measurements, each
study subject was seen by different staff throughout the
course of the study and therefore the variability of the
measurement process should not introduce any bias when
comparing across treatments.
Future studies will need to consider another approach
to providing uniform counseling (e.g., identifying key
behavioral topics for each session, or the use of online
programs), collecting body measurements uniformally
(e.g., iDEX), and investigating potential tailoring of a
behavioral weight management intervention to LLLT.
Conclusion
While there has been some concern regarding the safety
of LLLT, in this small pilot study we did not find any
indication of harmful effects based on the biomarkers or
self-reported side effects, which provides some initial sup-
port for LLLT being a safe intervention. It appears that
LLLT targets central adiposity, and our finding of reduc-
tion in waist circumference supports this premise. Further
exploration utilizing a larger sample size with longer dur-
ation of treatment and follow-up is warranted to assess
the safety and efficacy of LLLT in the treatment of obesity.
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